Consent Decree Finalized Against Philips Respironics
Details of the finalized consent decree against Philips Respironics, sparked by the potential health risks of its CPAP devices, are revealed.
Details of the finalized consent decree against Philips Respironics, sparked by the potential health risks of its CPAP devices, are revealed.
Until the requirements of the consent decree are met, Philips Respironics will not sell new CPAP, BiPAP, or other respiratory care devices in the US.
Customers are welcoming Philips Respironics CPAP devices back in markets around the globe, according to Philips CEO Roy Jakobs.
Following warnings that CPAP masks with magnetic closures may interfere with certain medical devices and implants, sleep physicians have questions. Here’s what to know.
Read MorePhilips raised its 2023 earnings outlook following an uptick in third-quarter sales, despite ongoing challenges related to its CPAP and ventilator device recall.
Read MoreUS Senator Dick Durbin and US Representative Jan Schakowsky have introduced legislation to reform medical device recalls in an effort to improve patient safety.
Read MoreSen. Richard Blumenthal is calling for “immediate, aggressive action” against Philips for keeping known defects with the company’s CPAP machines secret.
Read MorePhilips Respironics says it plans to conduct additional testing on certain CPAP and respiratory devices involved in its June 2021 recall at the request of the FDA.
Read MoreProPublica and the Pittsburgh Post-Gazette have filed suit against the US Food and Drug Administration, accusing the agency of holding back records related to the recall of breathing machines.
Read MoreA look at answers to some of the most critical questions about the ongoing recall of millions of CPAP machines, ventilators, and other breathing devices.
Read MoreTo understand the breakdowns that led to one of the most tumultuous medical device recalls in generations, ProPublica and the Pittsburgh Post-Gazette spent a year probing what happened inside Philips Respironics after the company first learned that contaminants were turning up in breathing machines designed to save lives.
Read MoreExor NV, a Netherlands-based diversified holding company, has bought a 15% stake in Royal Philips, with an option to increase it to 20%.
Read MorePhilips Respironics provided the latest results and conclusions on the comprehensive test and research program to assess potential health risks related to the polyester-based polyurethane sound abatement foam in specific sleep therapy and ventilator devices under the voluntary June 2021 recall.
Read MorePhilips Respironics provided an update on the field action for specific sleep therapy and ventilator devices involved in the company’s ongoing recall.
Read MoreThe FDA updated its Philips Respironics recall safety communication to provide updated information about medical device reports that the agency received from Jan 1 to March 31.
Read MoreRoyal Philips’ CEO says the third-party risk assessments for the sleep therapy devices under the June 2021 recall are “positive and reassuring.”
Read MorePhilips provides an update on field action for specific sleep therapy and ventilator devices involved in the company’s ongoing recall.
Read MoreThe FDA says Philips’ published number of repairs and replacements includes manufactured repair kits that Philips shipped internally to its facilities.
Read More